COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
Other: MR-Pro-ADM
Dosage of MR-pro-ADM
Inclusion Criteria:
- Any adult patient admitted in the ICU with COVID-19 pneumonia
Exclusion Criteria:
- Pregnancy
- Legal reasons (patients under guardianship, curatorship)
- Patient's refusal
Hospital of Arras
Arras, France
Hospital of Boulogne/mer
Boulogne-sur-Mer, France
Hospital of DOUAI
Douai, France
Hospital of Dunkerque
Dunkerque, France
Hospital Dr Schaffner
Lens, France
Hospital of Roubaix
Roubaix, France
Hospital of Tourcoing
Tourcoing, France
Hospitalier of Valenciennes
Valenciennes, France